ScholarIQanswers from OpenAlex

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

PaperCitations, authors & open-access status

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program have?

ScholarIQcitation count

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program has 122 citations in the OpenAlex counts ScholarIQ stores.

When was Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program published?

ScholarIQyear

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program has 2019 year in the ScholarIQ index.

What is the open-access status of Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

ScholarIQoa status

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program has hybrid oa status in the ScholarIQ index.

What is the DOI of Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

ScholarIQdoi

The DOI for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is on the source record.

What is the PMID of Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

ScholarIQpmid

The PMID for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is on the source record.

What is the OpenAlex record for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program?

ScholarIQopenalex

The OpenAlex for Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial